people in Switzerland suffer from diabetes.
Type 2 diabetes makes up approximately
of all cases of diabetes diagnosed in adults.
«More and more people are getting diabetes. The late effects are serious and the risk factors are manifold. We support information and education about the disease and are committed to continuously improving treatment options for patients.»
Helgo Magnussen, Director Business Unit Primary Care & Vaccines, MSD Switzerland
Type 2 diabetes is a chronic condition, which develops gradually and is characterised by increased blood sugar levels. It occurs when the pancreas does not produce enough insulin or the body is unable to use the insulin effectively to convert blood sugar into energy (insulin resistance). In most cases, type 2 diabetes does not develop until later in the patient’s life. At first, it does not cause any detectable symptoms. The condition often goes undetected until complications arise, such as wounds not healing properly or being prone to infection or visual impairments. Type 2 diabetes is affecting an increasing number of younger people who are severely overweight.
Type 2 diabetic patients under 55 years of age have a greatly increased risk of heart attacks.
People with type 2 diabetes are 1.5 – 2 times more likely than the general population to suffer a stroke.
52% of deaths among people with type 2 diabetes are the result of a cardiovascular disease.
When treating type 2 diabetes, it is vitally important to normalise the patient’s increased blood sugar levels. Switching to a healthier diet and exercising more does help, but in many cases it is not enough. These patients also rely on antidiabetics (drugs that reduce blood sugar) and regular visits to their doctor.
Diabetes is a chronic illness and, as yet, there is still no cure for it. MSD has been actively conducting research into diabetes for years, to enable us to provide patients with new, innovative treatment options.
With an unwavering focus on innovation and substantiated science, we are working on researching, developing and providing drugs and vaccines. In 2007, our long-standing research programme for diabetes enabled us to contribute to one of the most important advances in type 2 diabetes treatment: the introduction of a new class of treatment known as DPP-4 inhibitors. Although diabetes patients have seen their quality of life improve considerably, there are still many who do not reach their target blood sugar levels. Nowadays, there is a new class of antidiabetic substances used to treat type 2 diabetes, known as SGLT-2 inhibitors. This gives patients further options for combination and supplementary therapy for treating type 2 diabetes.